email article
Starting heparin prophylaxis within 24 hours of admission for COVID-19 was linked to substantially better outcomes in a VA study.
Early anticoagulation was associated with 27% lower relative risk of 30-day mortality than no anticoagulation (14.3% vs 18.7%, HR 0.73, 95% CI 0.66-0.81), Christopher Rentsch, PhD, of the London School of Hygiene & Tropical Medicine and VA Connecticut Healthcare System in New Haven, and colleagues reported in
Preventive heparin use held similar advantages for inpatient mortality (HR 0.69, 95% CI 0.61-0.77) as well as initiation of therapeutic anticoagulation (HR 0.81, 95% CI 0.73-0.90), the latter serving as a proxy for thromboembolic events and other clinical deterioration. These findings provide strong real world evidence to support guidelines recommending the use of prophylactic anticoagulation as initial treatment for patients with COVID-19 on hospital admission, the researchers concluded.
BW Businessworld
Roche Arthritis Drug Reduces COVID-19 Deaths In Trial In Hospitalised Patients
Actemra rose to become Roche s fifth-best-selling drug, at more than $3 billion, with nearly $600 million from COVID-19 treatment.
Photo Credit :
Roche s arthritis drug tocilizumab cuts the risk of death among patients hospitalised with severe COVID-19, also shortening the time to recovery and reducing the need for mechanical ventilation, results of a large trial showed on Thursday.
The findings - from the RECOVERY trial, which has been testing a range of potential treatments for COVID-19 since March 2020 - should help clear up confusion about the potential benefits of tocilizumab for COVID-19 patients after a slew of recent mixed trial results.